Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges
Clinical Microbiology and Infection · 2025-01 · 31 (1) · 29-36
DOI: 10.1016/j.cmi.2024.08.006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology and Infection, 2025-01. Verfasst von Maddalena Giannella und 7 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater…. Hauptthemen laut MEDLINE: Antifungal Agents, Immunocompromised Host, Invasive Fungal Infections, Drug Resistance, Fungal. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
BACKGROUND: Invasive fungal disease (IFD) causes morbidity and mortality in immunocompromised hosts (ICHs). Based on increasing recognition of the impact of IFD on human disease, a recent WHO priority list identified key areas of need. OBJECTIVES: This review examines changes in the epidemiology of IFD, in particular the emergence of antifungal-resistant pathogens and the current availability of rapid diagnostic tests and antifungal treatment options. SOURCES: Literature between 2000 and January 2024 regarding fungal epidemiology, diagnostic tests, antifungal resistance, emerging fungal pathogens, and novel antifungal agents in both adult and paediatric ICH were reviewed. CONTENT: We describe the changing epidemiology and continued burden and mortality of IFD in ICH. Furthermore, we discuss the emergence of antifungal-resistant organisms driven by new immunosuppressed populations, climate change, and antifungal exposure in the individual and environment. We highlight novel antifungal agents and how they will address current unmet needs. IMPLICATIONS: The changing epidemiology and increased population at risk for IFD, lack of recognition or quantification of risks for IFD with new therapies, current gaps in the availability of rapid diagnostic tests, and the imminent availability of novel antifungals with distinct spectra of activity argue for improved availability of and access to rapid diagnostics, antifungal stewardship programmes, and global access to antifungal agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy; European Society of Clinical…
- Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland; Infectious Diseases Department, Necker-Enfants Malades Hospital, Paris Cité University,…
- Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland; Laboratoire de Parasitologie-Mycologie, AP-HP, Hôpital Saint-Louis, Paris, France; Inst…
- Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland; Infectious Disease Research Program, Center for Bone Marrow Transplantation and Departm…
- European Society of Clinical Microbiology and Infectious Diseases Study Group for Infections in Compromised Hosts (ESCICH/ESCMID), Basel, Switzerland; Department of Infectious Diseases and Hospital Epidemiology, Univers…
- Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland; Mycology Reference Laboratory, Spanish National Centre for Microbiology, Instituto de S…
Förderung
- National Health and Medical Research Council
Zitieren
APA
Giannella, M., Lanternier, F., Dellière, S., Groll, A. H., Mueller, N. J., Alastruey-Izquierdo, A., Slavin, M. A., & ECCMID study groups on Invasive Fungal Infection and Infection in Immunocompromised Hosts (2025). Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges. Clinical Microbiology and Infection, 31(1), 29-36. https://doi.org/10.1016/j.cmi.2024.08.006
Vancouver
Giannella M, Lanternier F, Dellière S, Groll AH, Mueller NJ, Alastruey-Izquierdo A, et al. Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges. Clinical Microbiology and Infection. 2025;31(1):29-36. doi:10.1016/j.cmi.2024.08.006
BibTeX
@article{Giannella2025,
author = {Giannella, Maddalena and Lanternier, Fanny and Dellière, Sarah and Groll, Andreas H and Mueller, Nicolas J and Alastruey-Izquierdo, Ana and Slavin, Monica A and ECCMID study groups on Invasive Fungal Infection and Infection in Immunocompromised Hosts, ECCMID study groups on Invasive Fungal Infection and Infection in Immunocompromised Hosts},
title = {Invasive fungal disease in the immunocompromised host: changing epidemiology, new antifungal therapies, and management challenges},
journal = {Clinical Microbiology and Infection},
year = {2025},
volume = {31},
number = {1},
pages = {29--36},
doi = {10.1016/j.cmi.2024.08.006}
}
EUVIMED